As of November 8, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Organogenesis Holdings Inc. The largest reported stake is Glenn H. Nussdorf's, at 9.7%. 4 filings are on record since August 14, 2025 (Schedule 13D/A, November 3, 2025).
Sell to companies like Organogenesis Holdings Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: First Light Asset Management, LLC · Sole voting: 0 · Shared voting: 3,611,616 · Sole dispositive: 0 · Shared dispositive: 3,611,616 · SCHEDULE 13G/A, 2026-02-17
- · Reporting person: Soleus Capital Master Fund, L.P. · Sole voting: 0 · Shared voting: 9,985,951 · Sole dispositive: 0 · Shared dispositive: 9,985,951 · SCHEDULE 13G/A, 2026-02-12
- · Reporting person: Glenn H. Nussdorf · Sole voting: 10,994,161 · Shared voting: 1,254,399 · Sole dispositive: 10,994,161 · Shared dispositive: 1,254,399 · SCHEDULE 13D/A, 2025-11-03
- · Holder: Mathew P. Arens · Percent: 6.55% · SCHEDULE 13G
Organogenesis Holdings Inc. has 4 Schedule 13D or 13G filings on record since 2025-08-14. 2 holders' latest filing reports 5% or more of common stock, $0.01 par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 9.7% | 12,248,560 | SCHEDULE 13D/A, 2025-11-03 | 2025-05-14 | |
| Soleus Capital Master Fund, L.P. | 7.9% | 9,985,951 | SCHEDULE 13G/A, 2026-02-12 | 2025-12-31 |
| 3.06% | 3,888,816 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
Holding shares or following this stake? See who's behind Organogenesis Holdings Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Organogenesis Holdings Inc. and the records around it.
Organogenesis Holdings Inc. elsewhere on the record
Companies that share a holder
- First Light Asset Management, LLC also filed stake reports on 12 other companies: NeuroPace Inc (Sep 2026), Neogenomics, Inc. (Aug 2026), PALVELLA THERAPEUTICS, INC. (Aug 2026)
- Soleus Capital Master Fund, L.P. also filed stake reports on 24 other companies: Beta Bionics, Inc. (Nov 2026), Evolus, Inc (Nov 2026), INSPIRE MEDICAL SYSTEMS, INC. (Nov 2026)
Watch Organogenesis Holdings Inc.
Get an email when Organogenesis Holdings Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Organogenesis Holdings Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Organogenesis Holdings Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Organogenesis Holdings Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
5 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Glenn H. Nussdorf | 10,994,161 | 1,254,399 | 10,994,161 | 1,254,399 | SCHEDULE 13D/A, 2025-11-03 |
| GN 2016 Family Trust u/a/d August 12, 2016 | 918,680 | 0 | 918,680 | 0 | SCHEDULE 13D/A, 2025-11-03 |
| GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016 | 7,928,570 | 0 | 7,928,570 | 0 | SCHEDULE 13D/A, 2025-11-03 |
| Soleus Capital Master Fund, L.P. | 0 | 9,985,951 | 0 | 9,985,951 | SCHEDULE 13G/A, 2026-02-12 |
| Soleus Capital, LLC | 0 | 9,985,951 | 0 | 9,985,951 | SCHEDULE 13G/A, 2026-02-12 |
| Soleus Capital Group, LLC | 0 | 9,985,951 | 0 | 9,985,951 | SCHEDULE 13G/A, 2026-02-12 |
| Soleus Capital Management, L.P. | 0 | 9,985,951 | 0 | 9,985,951 | SCHEDULE 13G/A, 2026-02-12 |
| Soleus GP, LLC | 0 | 9,985,951 | 0 | 9,985,951 | SCHEDULE 13G/A, 2026-02-12 |
| Guy Levy | 0 | 9,985,951 | 0 | 9,985,951 | SCHEDULE 13G/A, 2026-02-12 |
| First Light Asset Management, LLC | 0 | 3,611,616 | 0 | 3,611,616 | SCHEDULE 13G/A, 2026-02-17 |
| Mathew P. Arens | 231,000 | 3,657,816 | 231,000 | 3,657,816 | SCHEDULE 13G/A, 2026-02-17 |
The latest filing names Organogenesis Holdings Inc., with its principal executive office as 85 DAN ROAD, CANTON, MA 02021 (SCHEDULE 13G/A, 2026-02-17).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Mathew P. Arens | 6.55% | SCHEDULE 13G |
| 2025-11-03 | Glenn H. Nussdorf | 9.7% | SCHEDULE 13D/A |
| 2026-02-12 | Soleus Capital Master Fund, L.P. | 7.9% | SCHEDULE 13G/A |
| 2026-02-17 | Mathew P. Arens | 3.06% | SCHEDULE 13G/A |
Questions about who owns Organogenesis Holdings Inc.
Who owns Organogenesis Holdings Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Organogenesis Holdings Inc.: Glenn H. Nussdorf (9.7%, Schedule 13D/A, filed 2025-11-03) and Soleus Capital Master Fund, L.P. (7.9%, Schedule 13G/A, filed 2026-02-12).
Who are the largest shareholders of Organogenesis Holdings Inc.?
By the share each holder's latest filing reports, the largest holders of Organogenesis Holdings Inc. on this page are Glenn H. Nussdorf (9.7%) and Soleus Capital Master Fund, L.P. (7.9%).
When did Glenn H. Nussdorf buy into Organogenesis Holdings Inc.?
The filings give report dates, not purchase dates. The earliest filing from Glenn H. Nussdorf on this page is the Schedule 13D/A, filed 2025-11-03, reporting 9.7%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 4 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Organogenesis Holdings Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 27, 2024 | Form D, private offering | $130M sold | Form D page | Source |
Tools for this story
Each opens in a new tab, filled in for Organogenesis Holdings Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.